In the short term, nonmedical switching (NMS) of stable patients with a rheumatic condition from originator biologics to biosimilars could have “considerable” short-term costs for a rheumatology medical center, according to a study presented at the annual European Congress of Rheumatology.
In the short term, nonmedical switching (NMS) of stable patients with a rheumatic condition from originator biologics to biosimilars could have “considerable” short-term costs for a rheumatology medical center, according to a study by Allan Gibofsky, MD, and colleagues that was presented at the annual European Congress of Rheumatology, held June 13-16, 2018, in Amsterdam.
The overall short-term costs associated with NMS were estimated to be £84,174 ($111,246) for the entire center; on average, that is a cost of £147 ($194) per switched patient.
The study estimated costs associated with NMS for stable patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) from the perspective of a rheumatology medical center in the United Kingdom. The researchers constructed an economic model using unit costs associated with provider/staff time and laboratory imaging tests derived from a literature search, and estimated both administrative burden for NMS program set-up and support and provider burden for initiating and managing NMS.
The study estimated that setting up an NMS program and subsequent administrative support costs £19,617 ($25,921) per center, which was attributed to:
After NMS set-up, provider burden for initiating and managing the switch was estimated to be £113 ($149) per switched patient. Assuming 5000 patients with relevant rheumatoid conditions in a medical center, it was estimated that 572 stable patients with RA, PsA, or AS would switch to biosimilars. The overall short-term cost associated with NMS was estimated to be £84,174 ($111,246) for the entire center, with 23% attributed to the NMS program set-up and support, and 77% attributed to extra provider time and monitoring (on average, a cost of £147 [$194] per switched patient).
Further study of costs related to NMS are needed to better weigh potential savings versus costs associated with NMS.
The researchers disclosed relationships with AbbVie and other pharmaceutical companies.
Reference
Gibofsky A, Garg V, Yang M, Qi CZ, Skup M. Estimating the short-term costs associated with non-medical switching in rheumatic diseases. Presented at the European League Against Rheumatism’s Annual European Congress of Rheumatology, June 13-16, 2018; Amsterdam, Netherlands. Abstract AB0416. doi: 10.1136/annrheumdis-2018-eular.7463.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.